An Explorative, Single Center, Open-labeled, Phase I Study to Evaluate the Feasibility and Safety of Intra-tumoral, Intra-peritoneal, and Subcutaneous Injections With IMP321 (LAG-3Ig Fusion Protein) for Advanced Stage Solid Tumor Entities

Trial Profile

An Explorative, Single Center, Open-labeled, Phase I Study to Evaluate the Feasibility and Safety of Intra-tumoral, Intra-peritoneal, and Subcutaneous Injections With IMP321 (LAG-3Ig Fusion Protein) for Advanced Stage Solid Tumor Entities

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Proof of concept
  • Acronyms INSIGHT
  • Most Recent Events

    • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
    • 31 Oct 2017 According to a Prima BioMed media release, information related to trial progress has been shard at the World Immunotherapy Congress 2017. Three patients have been recruited for Stratum A (intratumoral (i.t.)) and Stratum B (intraperitoneal (i.p.)) of the trial till date.
    • 19 Oct 2017 According to a Prima BioMed media release, information from the trial will be shared at the World Immunotherapy Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top